Reports Q1 revenue $321.39M, consensus $304.61M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “We are continuing to drive meaningful margin expansion and sustain profitable growth. We are gaining share in Plasma, advancing our impact in Hemostasis Management, and taking decisive steps to strengthen commercial execution in Vascular Closure. We remain well-positioned to achieve our ambitious long-range plan goals.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE: